The role of the cylooxygenase pathway in nociception and pain

被引：33
作者：
Bingham, Sharon
Beswick, Paul J.
Blum, David E.
Gray, Norman M.
Chessell, Iain P.
机构：
[1] GlaxoSmithKline, Neurol & Gastrointestinal CEDD, Harlow CM19 5AW, Essex, England
[2] GlaxoSmithKline, Neurol Med Dev Ctr, Res Triangle Pk, NC 27709 USA
来源：
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY | 2006年 / 17卷 / 05期
关键词：
COX-1; COX-2; pain; prostanoid; review;
D O I：
10.1016/j.semcdb.2006.09.001
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Cycloxygenase (COX) pathways have long been targeted for the treatment of inflammatory pain, initially through the use of NSAIDs. With the demonstration of two major COX isoforms, COX-1 and COX-2, involved in the production of prostanoids, but with different distribution and regulation, selective COX-2 inhibitors have been developed. This review covers factors influencing COX enzyme activity, the role of their products in the development and maintenance of pain and discusses recent safety concerns of COX-2 inhibitors. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码：544 / 554
页数：11
相关论文
共 95 条
[1]   The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity [J].
Agrawal, NGB ;
Matthews, CZ ;
Mazenko, RS ;
Woolf, EJ ;
Porras, AG ;
Chen, X ;
Miller, JL ;
Michiels, N ;
Wehling, M ;
Schultz, A ;
Gottlieb, AB ;
Kraft, WK ;
Greenberg, HE ;
Waldman, SA ;
Curtis, SR ;
Gottesdiener, KM .
JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (10) :1125-1131
[2]   Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers [J].
Agrawal, NGB ;
Porras, AG ;
Matthews, CZ ;
Woolf, EJ ;
Miller, JL ;
Mukhopadhyay, S ;
Neu, DC ;
Gottesdiener, KM .
JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (10) :1106-1110
[3]  
[Anonymous], 2004, LANCET, V364, P1287
[4]  
Belton O, 2000, CIRCULATION, V102, P840
[5]   The cyclooxygenase-2 inhibitor GW406381X [2-(4-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-pyrazolo[ 1,5-b]pyridazine] is effective in animal models of neuropathic pain and central sensitization [J].
Bingham, S ;
Beswick, PJ ;
Bountra, C ;
Brown, T ;
Campbell, IB ;
Chessell, IP ;
Clayton, N ;
Collins, SD ;
Davey, PT ;
Goodland, H ;
Gray, N ;
Haslam, C ;
Hatcher, JP ;
Hunter, AJ ;
Lucas, F ;
Murkitt, G ;
Naylor, A ;
Pickup, E ;
Sargent, B ;
Summerfield, SG ;
Stevens, A ;
Stratton, SC ;
Wiseman, J .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 312 (03) :1161-1169
[6]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[7]   Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].
Bresalier, RS ;
Sandler, RS ;
Quan, H ;
Bolognese, JA ;
Oxenius, B ;
Horgan, K ;
Lines, C ;
Riddell, R ;
Morton, D ;
Lanas, A ;
Konstam, MA ;
Baron, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102
[8]   Anti-inflammatory drugs: New multitarget compounds to face an old problem. The dual inhibition concept [J].
Celotti, F ;
Laufer, S .
PHARMACOLOGICAL RESEARCH, 2001, 43 (05) :429-436
[9]   Cyclooxygenase-1 is a marker for a subpopulation of putative nociceptive neurons in rat dorsal root ganglia [J].
Chopra, B ;
Giblett, S ;
Little, JG ;
Donaldson, LF ;
Tate, S ;
Evans, RJ ;
Grubb, BD .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2000, 12 (03) :911-920
[10]   Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E2-dependent plaque instability [J].
Cipollone, F ;
Prontera, C ;
Pini, B ;
Marini, M ;
Fazia, M ;
De Cesare, D ;
Iezzi, A ;
Ucchino, S ;
Boccoli, G ;
Saba, V ;
Chiarelli, F ;
Cuccurullo, F ;
Mezzetti, A .
CIRCULATION, 2001, 104 (08) :921-927
12345678910